Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8650339 | 0.87 | TDP1 (0.43) | PLA2G4AALDH1A1 | |
| SCHEMBL1058273 | 0.86 | PLA2G4A (0.38) | PLA2G4AHTT | |
| SCHEMBL4206545 | 0.85 | KDM4E (0.44) | PLA2G4AALDH1A1HTT | |
| SCHEMBL5211347 | 0.85 | LDHA (0.42) | PLA2G4AALDH1A1 | |
| SCHEMBL4976795 | 0.83 | PLOD2 (0.38) | PLA2G4AALDH1A1POLBSMN1; SMN2CA2 | |
| SCHEMBL31412009 | 0.83 | KDM4E (0.42) | PLA2G4AALDH1A1HTT | |
| SCHEMBL19320233 | 0.83 | PLA2G4A (0.43) | PLA2G4AMEN1KMT2A | |
| SCHEMBL11983873 | 0.81 | CYP2C19 (0.41) | PLA2G4AALDH1A1CA2 | |
| SCHEMBL11983876 | 0.79 | PLA2G4A (0.33) | PLA2G4A | |
| SCHEMBL12603663 | 0.79 | MGAM (0.44) | PLA2G4AALDH1A1HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253623-A1 | IRIDIUM COMPLEX PRODUCTION METHOD | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253623-A1 | IRIDIUM COMPLEX PRODUCTION METHOD | IPMK, TALDO1, BCKDK | PLA2G4A 3799/4885ALDH1A1 1033/4885POLB 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.